Climedo Establishes Advisory Board to Enter its Next Growth Chapter

Climedo Establishes Advisory Board to Enter its Next Growth Chapter


March 20, 2024

Munich, Wednesday, March 20, 2024 – Climedo, the leading European provider of eCOA and Real-World Evidence (RWE) solutions, proudly welcomes two distinguished industry leaders, Andreas Müller and Professor Lothar Färber, to its advisory board. The joint goal is to accelerate patient access to life-changing treatments. 

Andreas Müller is a seasoned executive renowned for his leadership in enterprises and startup ventures alike. With a track record spanning over 15 years in Life Sciences, including roles at Roche and more recently as Global Pharma CIO at Novartis, he now brings his expertise to various board positions in innovative companies. Throughout his career in Life Sciences, Andreas has demonstrated an unwavering commitment to improving access to innovative medicines.

“Joining Climedo’s advisory board is an exciting opportunity,” says Andreas Müller. “I look forward to actively contributing to a company that is leveraging Real-World Evidence with real-time insights into treatment success at both the patient and healthcare professional (HCP) level. Climedo’s patient-centric approach and innovative technology are transforming how we utilize data and I’m privileged to be part of this journey, fuelled by my overarching purpose, ‘patients can’t wait‘.”

Prof. Lothar Färber MD PhD, is a professor of pharmacology at Regensburg University, Germany. Over the course of his career, he has held various managerial positions in large pharmaceutical companies, his most recent assignment being CSO (Chief Science Officer) at Novartis. Over the past three decades, Prof. Färber oversaw 500+ clinical trials (Phases I to IV) across a variety of indications. He also holds an executive MBA from Harvard Business School, Boston.

Prof. Färber expressed his enthusiasm, stating, “I am eager to lend my expertise to Climedo’s mission of boosting medical research and enhancing patient outcomes. Drawing from three decades of clinical research experience, I truly appreciate the vital importance of actively involving HCPs. Climedo’s ‘data to dialogue’ approach resonates deeply with me, and I am excited to collaborate with the team to maximize its impact.”

“We are delighted to announce the addition of Andreas Müller and Prof. Lothar Färber to Climedo’s board,” says Sascha Ritz, Co-Founder and CEO of Climedo. “Their combined industry and scientific expertise will be instrumental in accompanying Climedo as we continue to revolutionize patient-centric RWE studies. We look forward to their valuable contributions.”

Climedo extends a warm welcome to Andreas Müller and Prof. Lothar Färber.


About Climedo

Climedo offers an all-in-one eCOA and EDC solution with hybrid capabilities for non-interventional studies and real-world evidence. By using a patient-centric approach and leveraging real-time data insights and visualizations around a study’s current progress, Climedo empowers its clients to better engage with healthcare professionals and other key opinion leaders (KOLs). This boosts awareness, stimulates scientific dialogue and accelerates the launch success of new medical innovations, thus reaching more patients faster. Founded in Munich in 2017, Climedo is a leading trusted partner for pharma, medtech, CROs and academia with over 1.7 million patients enrolled to date. Learn more at